1 - 6 of 6
1
Conference item icon
Conference item

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial

  • Aung, T, Buck, GAN, Parish, S, et al.
  • 2017-08-29
2
Conference item icon
Conference item

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial

  • Rocca, B, Buck, G, Petrucci, G, et al.
  • 2020-11-25
3
Conference item icon
Conference item

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

  • Emberson, J, Armitage, J, Ng, L, et al.
  • 2005-09-01
4
Conference item icon
Conference item

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS

  • Bulbulia, R, Bowman, L, Wallendszus, K, et al.
  • 2007-03-06
5
Conference item icon
Conference item

Large-scale clinical trials: Reliable answers in cardiovascular medicine

  • Bowman, L
  • 2006-06-01
6
Conference item icon
Conference item

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

  • Emberson, J, Armitage, J, Ng, L, et al.
  • 2005-10-25
FILTER RESULTS

TO TOP